News
AstraZeneca and Daiichi Sankyo's Dato-DXd can't show a significant improvement in overall survival in lung cancer trial, but they say the trend is clinically meaningful.
AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer, TROP2-directed Datroway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback